Journal
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
Volume 19, Issue 2, Pages 137-145Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14787210.2020.1812385
Keywords
SARS-CoV-2; COVID-19; miRNA; nanotherapeutics; nanoparticles
Ask authors/readers for more resources
This review outlines the association of COVID-19 with SARS and MERS, discusses the potential role of miRNAs in the pathogenesis of COVID-19, and highlights the therapeutic potential of miRNAs and their effective delivery for the treatment of COVID-19, emphasizing the importance of utilizing nanotechnology for developing miRNAs as therapeutic molecules in fighting against the pandemic.
Introduction The novel coronavirus (CoV) disease 2019 (COVID-19) is a viral infection that causes severe acute respiratory syndrome (SARS). It is believed that early reports of COVID-19 cases were noticed in December 2019 and soon after it became a global public health emergency. It is advised that COVID-19 transmits through human to human contact and in most cases, it remains asymptomatic. Several approaches are being utilized to control the outbreak of this fatal viral disease. microRNAs (miRNAs) are known signature therapeutic tool for the viral diseases; they are small non-coding RNAs that target the mRNAs to inhibit their post-transcriptional expression, therefore, impeding their functions, can serve as watchdogs or micromanagers in the cells. Areas covered This review work delineated COVID-19 and its association with SARS and Middle East respiratory syndrome (MERS), the possible role of miRNAs in the pathogenesis of COVID-19, and therapeutic potential of miRNAs and their effective delivery to treat COVID-19. Expert opinion This review highlighted the importance of various miRNAs and their potential role in fighting with this pandemic as therapeutic molecules utilizing nanotechnology.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available